Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) Equity Ratio (2019 - 2026)

ADC Therapeutics has reported Equity Ratio over the past 8 years, most recently at 0.74 for Q1 2026.

  • Quarterly results put Equity Ratio at 0.74 for Q1 2026, up 15.08% from a year ago — trailing twelve months through Mar 2026 was 0.74 (up 15.08% YoY), and the annual figure for FY2025 was 0.58, up 8.63%.
  • Equity Ratio reached 0.74 in Q1 2026 per ADCT's latest filing, down from 0.58 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.06 in Q1 2023 and bottomed at 0.87 in Q1 2025.
  • Median Equity Ratio over the past 5 years was 0.53 (2024), compared with a mean of 0.45.
  • The largest annual shift saw Equity Ratio crashed 2209.98% in 2023 before it grew 15.08% in 2026.
  • Over 5 years, Equity Ratio stood at 0.02 in 2022, then plummeted by 2209.98% to 0.42 in 2023, then tumbled by 50.62% to 0.63 in 2024, then rose by 8.63% to 0.58 in 2025, then decreased by 29.08% to 0.74 in 2026.
  • Business Quant data shows Equity Ratio for ADCT at 0.74 in Q1 2026, 0.58 in Q4 2025, and 0.82 in Q3 2025.